USPTO issues 2 patents for Enveric supporting EVM301 & EVM201 series compounds

Enveric Biosciences (ENVB) announced that the United States Patent and Trademark Office USPTO has issued two U.S. Patents, Nos. 12,133,856 the ‘856 patent and 12,138,276, the ‘276 patent bringing the total number of issued patents supporting its EVM301 series molecules to 11. The claims of the ‘856 patent and the ‘276 patent expand the range of protection for novel, non-obvious multi-substituent and halogenated psilocybin derivative compounds and pharmaceutical formulations containing such compounds, respectively…In addition, Enveric announced that the USPTO has issued two other U.S. Patents, No. 12,065,404 and 12,077,498 , related to its EVM201 series prodrug molecules. The claims of the ‘404 patent and ‘498 patent protect novel, non-obvious C4-carboxylic acid-substituted tryptamine derivative compounds and pharmaceutical drug formulations containing such compounds, and methods of making such compounds, respectively. These compounds are prodrugs intended to treat neurological disorders. Enveric recently announced that it licensed its EVM201 Series to MycoMedica Life Sciences MycoMedica . These additional patents strengthen and underscore the potential value to Enveric and MycoMedica, which plans to develop the lead EVM201 Series compound EB-002. “These patent issuances from the USPTO add important pillars to Enveric’s intellectual property portfolio as we continue to distinguish the pre-clinical performance of our tryptamine-based molecules under development for the treatment of mental health disorders from others on the market or under development,” said Joseph Tucker, Ph.D., Director and CEO of Enveric. “Importantly, with our focus squarely on our EVM301 Series, we expect to continue uncovering positive data highlighting the promising properties of EB-003, which is designed to capitalize on the potential for inducing neuroplasticity without causing hallucinations that can meet key commercial and regulatory criteria to advance to clinical trials.” Enveric has announced out-licensing deals with MycoMedica and Aries Science & Technology, which positions Enveric to focus its resources on development of its lead compound EB-003. These deals establish potential future income streams to support the development and commercialization of Enveric’s pipeline candidates…